(S)-10-Hydroxycamptothecin
(S)-10-Hydroxycamptothecin is a DNA topoisomerase I inhibitor, it is a clinical therapy agent against hepatoma.
Inquire / Order:
manager@chemfaces.com
Technical Inquiries:
service@chemfaces.com
Tel:
+86-27-84237783
Fax:
+86-27-84254680
Address:
1 Building, No. 83, CheCheng Rd., Wuhan Economic and Technological Development Zone, Wuhan, Hubei 430056, PRC
Providing storage is as stated on the product vial and the vial is kept tightly sealed, the product can be stored for up to
24 months(2-8C).
Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20C. Generally, these will be useable for up to two weeks. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.
Need more advice on solubility, usage and handling? Please email to: service@chemfaces.com
The packaging of the product may have turned upside down during transportation, resulting in the natural compounds adhering to the neck or cap of the vial. take the vial out of its packaging and gently shake to let the compounds fall to the bottom of the vial. for liquid products, centrifuge at 200-500 RPM to gather the liquid at the bottom of the vial. try to avoid loss or contamination during handling.
Nat Prod Sci.2014, 20(3):182-190
Korean Journal of Pharmacognosy2014, 113-120
Toxins (Basel).2021, 13(9):593.
Biomed Chromatogr.2016, 30(10):1573-81
European Journal of Integrative Medicine2018, 20:165-172
Evid Based Complement Alternat Med.2021, 2021:6687513.
Korean J. Medicinal Crop Sci.2022, 30(2):124-133
Oncotarget.2017, 9(3):4161-4172
Molecules.2020, 25(21):5087.
Arch Toxicol.2017, 91(10):3225-3245
Related and Featured Products
Cancer Treat Rep. 1983 Feb;67(2):179-82.
Action of (S)-10-hydroxycamptothecin on P388 leukemia and distribution of the drug in mice.[Pubmed:
6825126]
METHODS AND RESULTS:
As an inhibitor of the growth of P388 leukemia in mice, (S)-10-Hydroxycamptothecin (OPT) was as potent as the parent compound camptothecin (CPT). Incorporation of thymidine into DNA was the parameter most sensitive to OPT in vitro (ED50 approximately 4 micrograms/ml), but incorporation of cytidine into RNA and of acetate into lipids was also reduced significantly in the presence of the drug. The cytofluorometric profile suggested suppression of the S and G2/M phases. The distribution of OPT in mice at 2 and 24 hours after ip injection (10 mg/kg) was essentially similar to that of CPT, with the exception of a somewhat greater concentration of CPT in the liver.
CONCLUSIONS:
In their pharmacology, OPT and CPT appear to be very similar, despite reports that the hydroxy derivative is less toxic.
Anticancer Res. 1981;1(2):115-9.
Anti-tumor effect of (S)-10-hydroxycamptothecin on mouse hepatoma BW7756 and its possible mode of action.[Pubmed:
7347154]
METHODS AND RESULTS:
(S)-10-Hydroxycamptothecin (OPT), an analog of camptothecin (CPT), was found to inhibit the growth of the mouse hepatoma BW7756, when given at 1.0 mg/kg/day for 14 days. Cell cycle studies using flow cytofluorometry indicated that this drug inhibited the S-Phase of the tumor cells in vivo and the S and G2/M phases in vitro. Similar studies on host liver showed little or no effect. In spite of the narrow range of the effective dose of this drug against mouse hepatoma BW7756, the use of OPT in combination with other antitumor agents may be useful in primary hepatoma or liver metastases in view of its low toxicity towards host liver.
CONCLUSIONS:
A simple cytofluorometric method useful for live cell cycle study has been adapted for this investigation and can be adopted for other drug studies.
Int J Pharm. 2014 Apr 25;465(1-2):378-87.
A novel multifunctional poly(amidoamine) dendrimeric delivery system with superior encapsulation capacity for targeted delivery of the chemotherapy drug 10-hydroxycamptothecin.[Pubmed:
24530519]
With the aim of developing an efficient targeted delivery system for cancer therapy that overcomes drug leakage during circulation, we prepared a novel multifunctional dendrimeric carrier by integrating long hydrophobic C₁₂ alkyl chains, poly(ethylene glycol) chains and c(RGDfK) ligands presented on the surface. This dendrimer was able to tightly encapsulate the hydrophobic anticancer drug 10-Hydroxycamptothecin ((S)-10-Hydroxycamptothecin ,10-HCPT) through simple complexation and selectively target the drug to cancer cells overexpressing integrin αvβ₃ through high affinity interactions. The complex has a high loading efficiency, with each molecule encapsulating approximately 20 drug molecules; high stability, without any detectable drug release during dialysis for three days; and high water solubility, achieving an approximately 600-fold increase over the water solubility of free 10-Hydroxycamptothecin((S)-10-Hydroxycamptothecin ). This complex exhibited notably high cytotoxicity against 22RV1 cells overexpressing integrin αvβ₃ and a far lower cytotoxicity against MCF-7 cells, which express low levels of integrin αvβ₃. We expected encapsulated 10-Hydroxycamptothecin((S)-10-Hydroxycamptothecin ) to regain its anti-cancer activity following selective internalization of the complex into carcinoma cells via integrin receptor mediated endocytosis. As the drug remains inactive before internalization, this carrier has the ability to overcome problems associated with drug leakage in the circulation and off-target effects on normal tissues.
